Noble Conference Archives - Page 9 of 17

MondayFeb 17, 2020 10:00 am

Veritas Farms Inc. (VFRM) Starts Presentation at NobleCon16

Veritas Farms (OTCQB: VFRM) is a vertically integrated agribusiness focused on producing superior quality, whole plant, full spectrum hemp oils and extracts containing naturally occurring cannabinoids. Veritas currently owns and operates a 140-acre farm and production facilities in Pueblo, Colorado, and is registered with the Colorado Department of Agriculture to grow industrial hemp. The company markets and sells products under its Veritas Farms™ brand and manufactures private label products for a number of leading distributors and retailers. Veritas Farms™ brand full spectrum hemp oil products include vegan capsules, tinctures, formulations for sublingual applications and infused edibles, lotions, salves, and oral…

TuesdayJan 31, 2017 2:00 pm

Arch Therapeutics, Inc. (ARTH) Starts Presentation at NobleCon13

Arch Therapeutics (OTC: ARTH) operates as a life science medical device company. Arch develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery and trauma care. The company’s primary product candidate is AC5 Devices, a biocompatible synthetic peptide that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. For more information, visit the company’s website at www.archtherapeutics.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution…

TuesdayJan 31, 2017 2:00 pm

Cellectar Biosciences, Inc. (NASDAQ: CLRB) Starts Presentation at NobleCon13

Cellectar Biosciences (NASDAQ: CLRB) is engaged in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. It offers CLR 131, a PDC radiotherapeutic product candidate currently being evaluated in a phase I study for the treatment of relapse or refractory multiple myeloma; CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease ; CLR 124, a cancer-targeting positron emission tomography (PET) imaging PDC for the selective detection of tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting NIR-fluorophore optical imaging PDC for intraoperative tumor…

TuesdayJan 31, 2017 1:30 pm

BioTime, Inc. (NYSE: BTX) Starts Presentation at NobleCon13

BioTime (NYSE: BTX) is engaged in developing and commercializing novel therapies based on HyStem cell delivery and pluripotent stem cell technology platforms. The company focuses on regenerative medicine and is developing Renevia, currently in pivotal clinical trial for HIV related facial lipoatrophy; AST-VAC1, a cancer immunotherapy in phase II clinical trials for the treatment of acute myeloid leukemia; OpRegen, in phase I/IIa clinical trial to treat the dry form of age-related macular degeneration; and AST-OPC1, in phase I/II clinical trials for spinal cord injuries. The company also develops Premvia for wound management. For more information, visit the company’s website at www.biotimeinc.com.…

TuesdayJan 31, 2017 1:30 pm

Comtech Telecommunications Corp. (NASDAQ: CMTL) Starts Presentation at NobleCon13

Comtech Telecommunications (NASDAQ: CMTL) designs, develops, produces and markets products, systems and services for communications solutions. The company’s Commercial Solutions segment provides ground-based equipment; traveling wave tube amplifiers comprising high power narrow-band amplifiers that are used to amplify signals from satellite earth stations; and safety and security technology solutions that enable 911 call routing. This segment also offers enterprise application technologies, including location-based technology, such as Trusted Location, a software-based scoring system that allows providers to determine mobile location and identify fraudulent behavior and other security risks; and Look4, an application that enables customers to build their own applications. For…

TuesdayJan 31, 2017 1:30 pm

Aytu BioScience, Inc. (AYTU) Starts Presentation at NobleCon13

Aytu BioScience (OTC: AYTU) is a specialty healthcare company that focuses on developing and commercializing novel products in the field of urology in the United States. The company markets Natesto for the treatment of hypogonadism (low testosterone) in men; ProstaScint for use in newly diagnosed high-risk prostate cancer patients and patients with recurrent prostate cancer; and Primsol, an oral solution for urinary tract infections. It is also involved in commercializing of the RedoxSYS System for research use in various applications. In addition, the company is developing MiOXSYS, an in vitro diagnostic semen analysis test that is used in the quantitative…

TuesdayJan 31, 2017 1:00 pm

Torchlight Energy Resources, Inc. (NASDAQ: TRCH) Starts Presentation at NobleCon13

Torchlight Energy (NASDAQ: TRCH) engages in the acquisition, exploration, exploitation, and/or development of oil and natural gas properties in the United States. It has interests in four oil and gas projects, including the Marcelina Creek Field Development in Wilson County, Texas; the Ring Energy Joint Venture in Southwest Kansas; the Hunton play in Central Oklahoma; and the Orogrande project in Hudspeth County, Texas. It also had interest in a commercial salt water disposal facility in Seminole, Oklahoma. For more information, visit the company’s website torchlightenergy.com About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a…

TuesdayJan 31, 2017 1:00 pm

NovoCure Ltd. (NASDAQ: NVCR) Starts Presentation at NobleCon13

NovoCure (NASDAQ: NVCR) is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields (TTFields) for the treatment of solid tumor cancers. The company’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed phase 2 pilot trials investigating TTFields in non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma. Headquartered in Jersey, Novocure has operations in Portsmouth, New Hampshire; Malvern, Pennsylvania; and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Haifa, Israel. For more information, visit the company’s…

TuesdayJan 31, 2017 1:00 pm

Americas Silver Corp. (USAPF) Starts Presentation at NobleCon13

Americas Silver (OTC: USAPF) is a Canadian-based junior silver producer with assets in the Americas and a strong operating platform. Annual production for 2016 is expected to be 5.0 million-5.6 million silver equivalent ounces. The company has two established producing mines, a third mine in construction, and an advanced stage exploration project. Construction has commenced on the San Rafael project located in Mexico that will increase the company's silver equivalent production to 7.0 million-7.5 million ounces between $7 and $8 silver all in sustaining costs in 2018. For more information, visit the company’s website at www.americassilvercorp.com. About NetworkNewsWire NetworkNewsWire (NNW)…

TuesdayJan 31, 2017 1:00 pm

BioSpecifics Technologies Corp. (NASDAQ: BSTC) Starts Presentation at NobleCon13

BioSpecifics Technologies (NASDAQ: BSTC) is a biopharmaceutical company that engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren’s contracture and Peyronie’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. BioSpecifics is also involved in the development of other clinical indications for which collagenase…